This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holtzman, M. J. Search for Related Content PubMed PubMed Citation Articles by Holtzman, M. J.

Drug Development for Asthma

Pulmonary and Critical Care Medicine, Department of Medicine, and Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri

Address correspondence to: M. J. Holtzman, Washington University School of Medicine, Campus Box 8052, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail: holtzmanm{at}msnotes.wustl.edu

Asthma is characterized by abnormal immune cell accumulation and activation in the airways as well as dysfunction of specialized parenchymal cells. Research strategies to define asthma pathogenesis have focused on the hypothesis that this altered state is a consequence of an excessive allergen-driven response. Drug development for asthma has been directed at improving existing agents and expanding new modalities that target the Th2 allergic cascade. Significant opportunities are being pursued in each of these areas. However, this strategy may not account for some critical aspects of asthma pathogenesis. Alternative considerations include the need for a multidisciplinary approach to dissect the complexity of the asthma phenotype as well as a better understanding of nonallergic factors (especially viral reprogramming of airway behavior) in the development of the phenotype. Each of these considerations may provide an alternative strategy for further drug development for asthma and other complex diseases.

This article has been cited by other articles:

				E. M. Erin, B. R. Leaker, G. C. Nicholson, A. J. Tan, L. M. Green, H. Neighbour, A. S. Zacharasiewicz, J. Turner, E. S. Barnathan, O. M. Kon, et al. The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-{alpha} in Asthma Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 753 - 762. [Abstract] [Full Text] [PDF]

				A.-L. Andrews, J. W. Holloway, S. T. Holgate, and D. E. Davies IL-4 Receptor {alpha} Is an Important Modulator of IL-4 and IL-13 Receptor Binding: Implications for the Development of Therapeutic Targets. J. Immunol., June 15, 2006; 176(12): 7456 - 7461. [Abstract] [Full Text] [PDF]

				R. Baelder, B. Fuchs, W. Bautsch, J. Zwirner, J. Kohl, H. G Hoymann, T. Glaab, V. Erpenbeck, N. Krug, and A. Braun Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation J. Immunol., January 15, 2005; 174(2): 783 - 789. [Abstract] [Full Text] [PDF]

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]

				W. M. Abraham, A. Ahmed, I. Serebriakov, A. N. Carmillo, J. Ferrant, A. R. de Fougerolles, E. A. Garber, P. J. Gotwals, V. E. Koteliansky, F. Taylor, et al. A Monoclonal Antibody to {alpha}1{beta}1 Blocks Antigen-induced Airway Responses in Sheep Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 97 - 104. [Abstract] [Full Text] [PDF]